Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 1:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–40 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pediatric Epileptic Syndrome Clear all
Recruiting No phase listed Observational

ESIS in Pediatric DRE

NCT05469373
View directory record Official record
Conditions
Epilepsy
Interventions
Not listed
Lead sponsor
Sarah Katie Ihnen
Other
Eligibility
1 Year to 30 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Jul 24, 2026, 1:55 AM EDT
Suspended No phase listed Observational

International CDKL5 Registry

NCT04486768
View directory record Official record
Conditions
CDKL5 Deficiency Disorder (CDD)
Interventions
Survey Instrument
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
500 participants
Timeline
2018 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jul 24, 2026, 1:55 AM EDT
Completed Phase 1Phase 2 Interventional

An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome

NCT04442295
View directory record Official record
Conditions
Dravet Syndrome
Interventions
STK-001 - Single Ascending Doses, STK-001 - Multiple Ascending Doses
Drug
Lead sponsor
Stoke Therapeutics, Inc
Industry
Eligibility
2 Years to 18 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
18
States / cities
San Francisco, California • Aurora, Colorado • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated May 17, 2025 · Synced Jul 24, 2026, 1:55 AM EDT
Completed No phase listed Observational

A Prospective, Remote Observational Study in Pediatric Participants With Early-Onset SCN2A-Developmental and Epileptic Encephalopathy

NCT05407727
View directory record Official record
Conditions
SCN2A-DEE, Epilepsy
Interventions
Not listed
Lead sponsor
Praxis Precision Medicines
Industry
Eligibility
1 Year to 16 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Jul 24, 2026, 1:55 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)

NCT05818553
View directory record Official record
Conditions
SCN2A Encephalopathy, SCN8A Encephalopathy
Interventions
PRAX-562
Drug
Lead sponsor
Praxis Precision Medicines
Industry
Eligibility
1 Year to 18 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
Atlanta, Georgia • Chicago, Illinois • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Jul 24, 2026, 1:55 AM EDT
Completed Phase 3 Interventional Results available

A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome

NCT04938427
View directory record Official record
Conditions
Lennox Gastaut Syndrome (LGS)
Interventions
Placebo, Soticlestat
Drug
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 55 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
24
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Jul 24, 2026, 1:55 AM EDT
Recruiting Phase 1Phase 2 Interventional

A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy

NCT07227857
View directory record Official record
Conditions
Epileptic Encephalopathy
Interventions
S230815- Starting dose A, S230815- Dose B, S230815- Dose C, S230815- Dose D
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
2 Years to 12 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Orange, California • Boston, Massachusetts • Rochester, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jul 24, 2026, 1:55 AM EDT
Completed Phase 1 Interventional

Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome

NCT04062981
View directory record Official record
Conditions
Lennox Gastaut Syndrome
Interventions
Carisbamate
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
2 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
5
States / cities
Baltimore, Maryland • Lebanon, New Hampshire • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Jul 24, 2026, 1:55 AM EDT
Terminated Phase 2 Interventional Results available

Extension Study to Evaluate NBI-827104 in Pediatric Participants With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep

NCT05301894
View directory record Official record
Conditions
Epileptic Encephalopathy, Continuous Spike and Wave During Sleep
Interventions
NBI-827104
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
4 Years to 12 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
Orange, California • Aurora, Colorado • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jul 24, 2026, 1:55 AM EDT
Completed Phase 3 Interventional Results available

Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs

NCT01405053
View directory record Official record
Conditions
Lennox-Gastaut Syndrome
Interventions
Rufinamide, Any other approved Antiepileptic Drug
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
1 Year to 3 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
22
States / cities
San Diego, California • Aurora, Colorado • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Jul 24, 2026, 1:55 AM EDT
Terminated Phase 3 Interventional Results available

Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures

NCT04485104
View directory record Official record
Conditions
Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome, Seizure in Participants With Lennox-Gastaut Syndrome
Interventions
GWP42003-P
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Month to 23 Months
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Little Rock, Arkansas • Los Angeles, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Jul 24, 2026, 1:55 AM EDT
Terminated Phase 3 Interventional Results available

Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS

NCT01668654
View directory record Official record
Conditions
Epilepsy
Interventions
retigabine/ezogabine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 29 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
Los Angeles, California • Wellington, Florida • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Jul 24, 2026, 1:55 AM EDT
Completed Phase 3 Interventional

A Placebo-controlled Study of Levetiracetam In Children (1mo to 4yrs of Age) With Partial Onset Seizures.

NCT00175890
View directory record Official record
Conditions
Epilepsy, Partial
Interventions
Levetiracetam, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
1 Month to 4 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
42
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2020 · Synced Jul 24, 2026, 1:55 AM EDT
Recruiting No phase listed Observational

A Multicenter Pediatric Deep Brain Stimulation Registry

NCT06585618
View directory record Official record
Conditions
Dystonia, Epilepsy in Children, Cerebral Palsy, Tourette Syndrome, Obsessive-Compulsive Disorder, Neurologic Disorder, Movement Disorders in Children, Movement Disorders, Deep Brain Stimulation
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
0 Years to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Jul 24, 2026, 1:55 AM EDT
Recruiting Not applicable Interventional

A Multi-site Feasibility Clinical Trial of Retraining and Control Therapy (ReACT), a Mind and Body Treatment for Pediatric Functional Seizures

NCT05819268
View directory record Official record
Conditions
Functional Seizures, Convulsion, Non-Epileptic
Interventions
ReACT, CATCH-IT
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
11 Years to 18 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Jul 24, 2026, 1:55 AM EDT
Completed Phase 2 Interventional Results available

A Randomized, Controlled Trial of Ganaxolone in Patients With Infantile Spasms

NCT00441896
View directory record Official record
Conditions
Infantile Spasms
Interventions
Ganaxolone, Placebo
Drug · Other
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
4 Months to 24 Months
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
15
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Jul 24, 2026, 1:55 AM EDT